menu
    • menu
    [{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC \/ Optinose"},{"orgOrder":0,"company":"KALEO INC","sponsor":"pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC \/ pan Canadian Pharmaceutical Alliance"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KALEO INC \/ KALEO INC","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC \/ KALEO INC"}]

    Find Clinical Drug Pipeline Developments & Deals by KALEO INC

    Menu

    KALEO INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Epinephrine

    Therapeutic Area : Immunology

    Study Phase : Approved

    Recipient : Valeo Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Valeo Pharma Enters Into License Agreement with Kaléo for The Canadian Rights to Allerject®

    Details : Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.

    Product Name : Allerject

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    August 02, 2022

    Lead Product(s) : Epinephrine

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Recipient : Valeo Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Epinephrine

    Therapeutic Area : Immunology

    Study Phase : Approved

    Sponsor : pan Canadian Pharmaceutical Alliance

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Kaléo and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® Auto-Injector

    Details : Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.

    Product Name : Allerject

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    August 10, 2020

    Lead Product(s) : Epinephrine

    Therapeutic Area : Immunology

    Highest Development Status : Approved

    Sponsor : pan Canadian Pharmaceutical Alliance

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed

    KALEO INC

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate

    Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

    Study Phase : Approved

    Sponsor : Optinose

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

    Details : Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.

    Product Name : Xhance

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 08, 2020

    Lead Product(s) : Fluticasone Propionate

    Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

    Highest Development Status : Approved

    Sponsor : Optinose

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth